MedicGo
Detection and properties of TSH-binding inhibitor immunoglobulins in patients with Graves' disease and Hashimoto's thyroiditis.
Metadata
Journaljournal of clinical endocrinology & metabolism5.399Date
1978-May
Type
Journal Article
Volume
1978-May / 46 : 734-9
Author
Endo K , Kasagi K , Konishi J , Ikekubo K , Okuno T , Takeda Y , Mori T , Torizuka K
DoiPMIDMESH
Adolescent
Adult
Female
Graves Disease
Humans
Hyperplasia
Immunoglobulin G
Immunoglobulins, Thyroid-Stimulating
Long-Acting Thyroid Stimulator
Male
Thyroid Gland
Thyroiditis, Autoimmune
Thyroxine
Triiodothyronine
Abstract
TSH-binding inhibitor immunoglobulins (TBII) have been detected in patients with Graves' disease and Hashimoto's thyroiditis by using the radioreceptor assay of TSH. In untreated Graves' patients, TBII levels correlated well with thyroidal 99mTc uptake at 30 min and the grade of epithelial hyperplasia of thyroid follicles. There were many Graves' patients whose sera contained high TBII levels but no detectable bioassayable thyroid-stimulating activity (LATS), and in these patients, close correlation was observed between serum levels of TBII and bioassayable LATS-protector activity. TBII were detectable in 2 (10%) of 20 patients with Hashimoto's thyroiditis, both of whom were clinically hypothyroid. The serum or IgG fraction from one of them, however, did not contain any significant LATS, LATS-protector, or human thyroid adenylate cyclase-stimulating activity and caused inhibition of adenylate cyclase stimulation by TSH. In that patient, TBII may be acting to block TSH binding to TSH receptors, thus causing TSH unresponsiveness and hypothyroidism.
Fav
Like
Download
Share
Export
Cite
5.4
J Clin Endocrinol Metabjournal of clinical endocrinology & metabolism
Metadata
LocationUnited States
FromENDOCRINE SOC

No Data

© 2017 - 2020 Medicgo
Powered by some medical students